| Literature DB >> 22811591 |
Gerwald A Köhler1, Senait Assefa, Gregor Reid.
Abstract
Candida albicans is the most important Candida species causing vulvovaginal candidiasis (VVC). VVC has significant medical and economical impact on women's health and wellbeing. While current antifungal treatment is reasonably effective, supportive and preventive measures such as application of probiotics are required to reduce the incidence of VVC. We investigated the potential of the probiotics Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 towards control of C. albicans. In vitro experiments demonstrated that lactic acid at low pH plays a major role in suppressing fungal growth. Viability staining following cocultures with lactobacilli revealed that C. albicans cells lost metabolic activity and eventually were killed. Transcriptome analyses showed increased expression of stress-related genes and lower expression of genes involved in fluconazole resistance, which might explain the increased eradication of Candida in a previous clinical study on conjoint probiotic therapy. Our results provide insights on the impact of probiotics on C. albicans survival.Entities:
Mesh:
Year: 2012 PMID: 22811591 PMCID: PMC3395238 DOI: 10.1155/2012/636474
Source DB: PubMed Journal: Infect Dis Obstet Gynecol ISSN: 1064-7449
Bacterial and Candida albicans strains used in this study.
| Strain | Origin | Reference |
|---|---|---|
|
| Wild-type isolate | [ |
|
| Intestinal isolate | This study |
|
| Vaginal isolate | [ |
|
| Vaginal isolate | [ |
|
| Clinical isolate |
|
Figure 1Agar inhibition assays with bacteria, lactic acid, and C. albicans. The images in (a) show the results of deferred agar overlay assays on bacterial colonies (L. rhamnosus GR-1, L. reuteri RC-14, L. johnsonii PV016, and S. aureus ATCC 25923) and C. albicans as the tester organism. The bacteria were spotted on MRS or buffered MRS-MOPS (pH 7.0) plates. After incubation for 48 hrs, bacterial colonies were overlayed with soft agar containing live C. albicans cells and incubated for another 24 hrs. For details see Section 2. A C. albicans lawn developed, but fungal growth was inhibited around the Lactobacillus colonies (clear zones), most predominantly around the probiotic strains GR-1 and RC-14. No inhibition was found with S. aureus. On MRS-MOPS buffered to pH 7 inhibition zones are much smaller or absent indicating reduced effectiveness of the lactobacilli. (b) Shows the results of disk diffusion assays using lactic acid in the indicated molarities (20 μL per disk) as the inhibitory compound. Plates were inoculated to produce a lawn of C. albicans and disks with lactic acid were immediately placed on the inoculated plates. Following 24 hrs incubation, only the 6 M concentration of lactic acid showed an inhibition zone on MRS. Similar to the overlay assays, the inhibition zone on the buffered MRS-MOPS medium was largely reduced.
Figure 2Inhibition of C. albicans growth by lactic acid at low pH. Microplate growth assays were used to determine the effect of lactic acid on the growth of C. albicans. MRS medium was supplemented with 120 mM lactic acid and the pH was adjusted to pH 4.5 or 7.0. MRS with 120 mM lactic acid had a pH of 4.2. As a control for low pH, MRS was adjusted to pH 4.5 using hydrochloric acid (MRS (HCL)). While acidic pH slows growth of C. albicans, the strongest growth inhibition was achieved with lactic acid at low pH. This inhibitory effect was completely lost by neutralization. Error bars show the standard deviations of two experiments with quadruplicate measurements. Statistical significant (P < 0.01) differences to all other conditions as calculated by ANOVA are indicated by asterisks.
Figure 3Growth inhibition of C. albicans by culture supernatants from probiotic lactobacilli. Cell-free culture supernatants of L. rhamnosus GR-1 and L. reuteri RC-14 were collected after 48 hrs of growth and adjusted to pH 4.5 and pH 6.8 using sodium hydroxide. Varying amounts of the supernatants were added to MRS media inoculated with C. albicans in microtiter plates (total volume per well 200 μL). After incubation at 37°C for 24 hrs, the cell densities were determined by OD600 nm readings. The inhibitory effect of the supernatants at low pH was lost at pH 6.8. Error bars show the standard deviations of at least triplicate experiments.
Figure 4Viability assays of C. albicans cells following coculture with bacteria and exposure to lactic acid. (a) Microscopic viability assay: C. albicans cells were stained with the FUN 1 cell stain (Invitrogen) for viability after coculture with L. rhamnosus GR-1 (Ca + Lb-GR-1). A C. albicans culture without lactobacilli served as control (Ca). Cell images were obtained by confocal laser scanning microscopy. Results for the vital staining procedure are depicted above the images. White arrows in the zoomed insert image on the left indicate CIVS formation in metabolically active cells of the control culture. The presence of lactobacilli increases the number of metabolically inactive and dead cells (right image). (b) Fluorometric assay of C. albicans cells viability following 16 hr incubation in MRS, MRS (HCl) pH 4.5, and MRS (lactic acid) pH 4.5. Cell viability was measured by monitoring the conversion of FUN 1 to red fluorescent intravacuolar structures in a microplate assay. The red/green fluorescence ratio increases in the presence of viable, metabolically active cells, particularly within the first 30 min of the assay. Metabolically inactive cells show no increase of the red/green ratio. For assay details see Section 2. The figure shows the results of a representative experiment. Incubation of C. albicans cells in MRS at pH 4.5 in the presence of lactic acid appears to reduce cell viability much more than incubation in MRS that was adjusted to pH 4.5 using HCl. (c) Example of a fluorometric FUN 1 cell viability assay of C. albicans following coculture with L. rhamnosus GR-1, L. reuteri RC-14, L. johnsonii, or S. aureus. A C. albicans culture without bacteria served as control (Ca + MRS). GR-1 and RC-14 consistently caused the strongest reduction in C. albicans viability. All fluorometric experiments were conducted in triplicate. Error bars indicate standard deviations.
Figure 5Lactobacillus-C. albicans cocultures for transcriptome analysis. The experimental setup employing a 0.45 μm membrane for separation of the bacterial and fungal cultures in 6-well tissue culture plates is represented schematically in (a). Results of a typical Lactobacillus-C. albicans coculture and C. albicans-only control experiment are shown in (b). Growth of C. albicans and Lactobacillus (Lb) in the respective compartments was determined by OD600 nm readings (left y-axis). The pH of the culture media is depicted in dashed lines using the right y-axis. For transcriptome analysis, total RNA was isolated from C. albicans cells harvested from cocultures and controls.
(a) Upregulated C. albicans genes
| ORFa | Gene | Molecular functionb | Log phase cocultures | Late log to early stationary phase cocultures | |||||
|---|---|---|---|---|---|---|---|---|---|
| GR1_a | RC14_a | GR1_b | GR1_c | GR1_d | RC14_b | GR1_e | |||
| Amino acid metabolismc | |||||||||
| orf19.5610 |
| Ornithine carbamoyltransferase | 0.49 | 2.43 | −0.53 | 1.69 | 3.54† | 4.36† | 3.20† |
|
| |||||||||
| Carbohydrate metabolism | |||||||||
| orf19.3675 |
| Putative galactose-1-phosphate uridyl transferase | 0.69 | 2.12 | 1.55 | 6.12† | 3.40† | 4.11† | 0.47 |
| orf19.1788 |
| Putative xylulokinase | 0.39 | 2.26 | 0.37 | 3.24† | 2.91 | 4.33† | 3.06† |
|
| |||||||||
| Cell wall biosynthesis | |||||||||
| orf19.3688 | Putative chromatin DNA binding protein | 7.69† | 1.66 | 0.35 | 0.19 | 10.34† | 4.25† | −0.09 | |
| orf19.3674 |
| UDP-glucose 4,6-dehydratase with role in mannosylation of cell wall proteins | 0.11 | 1.70 | −0.06 | 3.63† | 4.48† | 4.75† | 0.21 |
|
| |||||||||
| Fatty acid metabolism | |||||||||
| orf19.5640 |
| Putative peroxisomal targeting receptor | 0.14 | −2.14 | 3.31† | 5.21† | 3.34† | 4.03† | 1.03 |
| orf19.5215 |
| Putative acyl-CoA thioesterase | −0.91 | −0.76 | 1.91 | 3.58† | 5.17† | 5.66† | −2.00 |
|
| |||||||||
| Glycogen metabolism | |||||||||
| orf19.3302 | Putative type-1 protein phosphatase targeting subunit | −0.61 | −0.98 | 0.58 | 3.03† | 6.26† | 3.28† | 1.32 | |
|
| |||||||||
| Glycolysis | |||||||||
| orf19.6116 |
| Glucokinase | −0.85 | 0.48 | 1.25 | 0.82 | 4.13† | 3.05† | 6.62† |
|
| |||||||||
| Intracellular transport | |||||||||
| orf19.3233 |
| Putative SH3-domain-containing protein | −1.94 | −0.81 | 2.30 | 3.34† | 5.24† | 3.66† | −0.24 |
| orf19.7086 | Putative protein transporter | 0.54 | −1.18 | −1.10 | 1.35 | 4.74† | 4.15† | 3.27† | |
| orf19.3841 | Putative protein serine/threonine kinase | −2.91 | −0.82 | −0.68 | 4.07† | 4.94† | 4.92† | −1.58 | |
|
| |||||||||
| Oxidation/Reduction | |||||||||
| orf19.5805* |
| D-lactate dehydrogenase* | 1.34 | 0.72 | 4.57† | 3.63† | 6.23† | 5.90† | 8.57† |
| orf19.1048 |
| Aldo-keto reductase | −0.09 | 2.07 | 1.36 | −0.92 | 5.16† | 3.41† | 6.71† |
| orf19.742 |
| Putative aldehyde dehydrogenase | −1.27 | 0.96 | −0.19 | 4.46† | 4.77† | 5.36† | 3.16† |
| orf19.5288 | IFE2 | Alcohol dehydrogenase | 1.03 | −0.07 | −0.66 | 5.77† | 6.75† | 6.04† | 0.33 |
|
| |||||||||
| Protein catabolism | |||||||||
| orf19.1191 | Possible ubiquitin-protein ligase | 1.12 | −0.91 | 3.14† | 2.25 | 3.64† | 4.31† | −0.45 | |
| orf19.5752 | Possible ubiquitin-protein ligase | −1.59 | −0.66 | 0.17 | 4.35† | 3.16† | 3.29† | 2.38 | |
|
| |||||||||
| Repair | |||||||||
| orf19.1331 |
| Protein may be involved in DNA mismatch repair | −0.74 | −2.27 | −0.14 | 4.18† | 8.78† | 6.68† | 5.39† |
|
| |||||||||
| Respiration | |||||||||
| orf19.4551 |
| Predicted carnitine acetyl transferase | 1.21 | 1.97 | 0.08 | 11.85† | 3.64† | 7.52† | 2.61 |
|
| |||||||||
| RNA catabolism | |||||||||
| orf19.5614 |
| Putative ribonuclease H1 | −1.33 | 0.38 | −0.07 | 3.06† | 4.11† | 2.96 | 3.22† |
|
| |||||||||
| Signaling | |||||||||
| orf19.399 | Putative serine/threonine protein kinase | −2.21 | −2.59 | −0.10 | 4.08† | 4.88† | 4.44† | −0.22 | |
| orf19.5531 |
| Chaperone for Crk1 protein kinase | −0.45 | 0.95 | 0.80 | 2.13 | 5.46† | 3.19† | 6.05† |
|
| |||||||||
| Stress response | |||||||||
| orf19.882* |
| Heat-shock protein* | 0.00 | −1.35 | 0.06 | 4.21† | 4.52† | 5.81† | 4.66† |
| orf19.3861* |
| Putative Type II HSP40 co-chaperone* | −0.91 | −0.40 | 0.79 | 1.65 | 3.92† | 4.78† | 3.10† |
| orf19.5348* |
| Trehalose-phosphate synthase subunit* | 0.59 | −0.26 | −0.99 | 4.23† | 8.95† | 7.42† | 5.40† |
|
| |||||||||
| Transcriptional regulation | |||||||||
| orf19.3047 |
| Protein kinase-related protein | 1.23 | 0.77 | 0.66 | 3.62† | 3.69† | 4.84† | 4.52† |
| orf19.909 |
| Putative transcription factor | −0.52 | −1.28 | 1.29 | 6.75† | 5.15† | 7.01† | 2.41 |
| orf19.3190 |
| Putative transcription factor involved in salt tolerance | 0.98 | 1.83 | 2.82 | 3.87† | 4.99† | 5.03† | −0.59 |
|
| |||||||||
| Translation | |||||||||
| orf19.154 | Possible 90S pre-ribosome complex protein | 9.04† | 1.52 | −0.03 | 4.19† | 3.22† | 2.77 | 0.90 | |
|
| |||||||||
| Transport | |||||||||
| orf19.5079* |
| ABC transporter* | 2.77 | 3.79† | −0.06 | 3.22† | 2.89 | 3.51† | 1.78 |
| orf19.4802 |
| Putative high affinity iron transporter (vacuolar) | −0.45 | 0.76 | 1.10 | 4.54† | 5.95† | 7.85† | −0.38 |
| orf19.3668 |
| Putative glucose transporter | 1.17 | 1.35 | 1.73 | 9.56† | 4.30† | 3.16† | −2.49 |
| orf19.5447 |
| Putative glucose/myo-inositol transporter | 2.51 | 3.11† | 2.55 | 4.67† | 2.95 | 5.05† | 5.41† |
| orf19.3526 |
| Inositol transporter | 1.82 | −0.20 | 1.69 | 3.52† | 5.21† | 5.25† | 2.91 |
| orf19.1979 |
| Putative glycerophosphoinositol permease | 0.97 | 6.75† | −1.94 | 3.73† | 5.82† | 8.01† | 1.64 |
| orf19.1027 |
| Phosphatidylinositol transfer protein | −0.47 | −1.63 | 0.61 | 2.19 | 3.61† | 4.23† | 3.05† |
| orf19.4737* |
| Possible polyamine transporter* | 0.08 | −0.02 | 3.65† | 4.30† | 4.59† | 7.16† | 3.48† |
| orf19.700* |
| Similar to permeases (↑weak acid stress)* | −0.79 | −1.34 | 4.50† | 4.90† | 2.88 | 5.02† | −0.14 |
|
| |||||||||
| Unknown | |||||||||
| orf19.2498 | Unknown | −2.12 | −1.08 | 0.29 | 3.03† | 3.05† | 3.99† | −0.55 | |
| orf19.5245 | Unknown | −0.36 | −1.74 | 1.59 | 0.84 | 5.03† | 5.24† | 4.78† | |
| orf19.6321 |
| Putative GPI-anchored protein of unknown function | −1.55 | −0.79 | 0.71 | −1.46 | 5.14† | 3.50† | 3.62† |
| orf19.5295 | Unknown | −0.76 | 1.02 | −2.03 | 5.83† | 3.06† | 3.51† | −1.02 | |
| orf19.3448 | Unknown | 1.02 | 0.86 | −0.59 | 5.89† | 2.51 | 3.32† | 3.52† | |
(b) C. albicans genes with mixed regulation
| ORFa | Gene | Molecular functionb | Log phase cocultures | Late log to early stationary phase cocultures | |||||
| GR1_a | RC14_a | GR1_b | GR1_c | GR1_d | RC14_b | GR1_e | |||
|
| |||||||||
| Amino acid metabolismc | |||||||||
| orf19.3974 |
| 1-Pyrroline-5-carboxylate dehydrogenase | −4.32# | −0.86 | −0.39 | 3.07† | −3.25# | −6.02# | −1.68 |
| orf19.105 |
| Put. phosphoadenosine-5′-phosphate phosphatase | −2.16 | −4.51# | 3.44† | 3.62† | −0.79 | 3.67† | −3.38# |
| orf19.5811 |
| Putative uroporphyrin-3 C-methyltransferase | 0.37 | 0.59 | 0.67 | 4.93† | −1.93 | 3.53† | −4.15# |
|
| |||||||||
| Carbohydrate metabolism | |||||||||
| orf19.7481 |
| Malate dehydrogenase | −1.68 | −2.14 | 1.19 | 3.97† | −3.66# | −3.34# | −1.21 |
|
| |||||||||
| Cell morphogenesis | |||||||||
| orf19.4892 |
| Subunit of cAMP-dependent protein kinase (PKA) | 0.19 | 1.68 | −3.02# | −1.85 | 2.69 | 3.01† | −3.77# |
|
| |||||||||
| Cell wall assembly | |||||||||
| orf19.377 |
| Putative beta-1,3-glucanosyltransferase | −1.11 | 0.74 | 3.09† | 3.46† | 1.67 | 1.60 | −3.52# |
|
| |||||||||
| Cytoskeleton maintenance | |||||||||
| orf19.3505 | Similar to | −0.04 | −4.18# | −1.26 | 0.59 | 5.35† | 3.91† | 0.07 | |
|
| |||||||||
| Filamentous growth | |||||||||
| orf19.4246 | Similar to | −1.10 | −4.36# | 0.89 | 4.67† | 3.16† | 2.66 | 3.93† | |
| orf19.860 |
| Putative beta-mannosyltransferase | −4.31# | 1.93 | 3.88† | 1.90 | −3.35# | −2.13 | −0.42 |
|
| |||||||||
| Oxidation/reduction | |||||||||
| orf19.7323 |
| Corticosteroid binding protein | −1.74 | 3.42† | 0.83 | 0.26 | −3.66# | −3.27# | −1.81 |
| orf19.6139 |
| Putative ferric reductase | −1.25 | 0.17 | 4.56† | −2.56 | −3.14# | −4.12# | −0.42 |
| orf19.6531 |
| NADH-ubiquinone oxidoreductase | −2.95 | 0.14 | 3.33† | −2.10 | −3.89# | −4.12# | −1.28 |
|
| |||||||||
| pH response | |||||||||
| orf19.101 |
| Unknown, involved in cellular response to pH | −0.73 | −0.50 | −0.84 | 2.43 | 3.69† | 3.75† | −3.08# |
|
| |||||||||
| Stress response | |||||||||
| orf19.3707* |
| Nitric oxide dioxygenase* | −0.61 | −1.54 | 1.07 | 4.53† | 2.61 | 5.15† | −3.06# |
| orf19.6232* |
| Predicted serine/threonine protein kinase* | −3.75# | −1.63 | 4.49† | 3.98† | −0.21 | 1.51 | −0.30 |
|
| |||||||||
| Transcription | |||||||||
| orf19.2831 |
| Putative RNA polymerase III subunit C31 | −0.70 | 3.18† | 2.42 | −3.33# | −3.63# | −2.32 | −1.66 |
| orf19.5908 |
| TEA/ATTS transcription factor | 2.31 | 2.20 | 1.74 | 6.57† | 1.81 | 4.84† | −4.97# |
| orf19.5992 |
| Transcriptional regulator of white-opaque switching | −1.25 | −3.19# | −0.42 | 6.58† | 6.05† | 8.17† | −3.00# |
|
| |||||||||
| Transport | |||||||||
| orf19.6578 | Predicted membrane transporter | 0.28 | −3.37# | −0.56 | 4.20† | 6.39† | 3.27† | 0.01 | |
|
| |||||||||
| tRNA aminoacylation | |||||||||
| orf19.5239 | similarity to alanyl-tRNA synthases | 0.30 | −4.73# | −3.55# | 0.74 | 0.58 | 3.76† | 0.69 | |
|
| |||||||||
| Unknown | |||||||||
| orf19.925 | −1.03 | −1.59 | 3.42† | −0.81 | −4.07# | −3.38# | 0.11 | ||
| orf19.599 | 2.89 | 4.04† | 4.02† | −3.40# | 0.51 | 0.33 | 2.02 | ||
| orf19.4765 |
| Putative GPI-anchored cell wall adhesin-like protein | −0.67 | 5.78† | −3.74# | −0.92 | −0.13 | −4.12# | 2.61 |
| orf19.6342 | 2.06 | 4.26† | −3.63# | −3.94# | 1.70 | 2.11 | 1.27 | ||
(c) Downregulated C. albicans genes
| ORFa | Gene | Molecular functionb | Log phase cocultures | Late log to early stationary phase cocultures | |||||
| GR1_a | RC14_a | GR1_b | GR1_c | GR1_d | RC14_b | GR1_e | |||
|
| |||||||||
| Adhesionc | |||||||||
| orf19.2122* |
| ALS family protein; role in adhesion, biofilm formation, germ tube induction* | −1.84 | −3.38# | 0.64 | 1.51 | −3.68# | −0.73 | −3.71# |
|
| |||||||||
| Amino acid metabolism | |||||||||
| orf19.646 |
| Putative glutamate synthase | −3.16# | −0.50 | 0.45 | 1.56 | −1.62 | −3.20# | −3.08# |
| orf19.3846 |
| Homoaconitase | −2.68 | −1.54 | 0.63 | −4.04# | −5.51# | −4.80# | −0.52 |
| orf19.2360 |
| Putative bifunctional carbamoylphosphate synthetase-aspartate transcarbamylase | −0.58 | −5.46# | −0.75 | −1.48 | −3.62# | −4.30# | −0.13 |
| orf19.6257 |
| Putative glutamate synthase | −0.80 | −3.46# | 0.19 | −3.07# | −5.30# | −3.61# | 0.29 |
|
| |||||||||
| Cell wall organization | |||||||||
| orf19.386 |
| Putative S-adenosylmethionine-homocysteine methyltransferase | −1.87 | −1.60 | 0.64 | −3.11# | −3.40# | −4.50# | −2.44 |
| orf19.3829* |
| Glycosidase of cell surface* | −4.84# | −4.20# | −3.95# | −7.74# | −3.17# | −6.66# | −5.39# |
| orf19.5171 |
| Protein mannosyltransferase, | −0.75 | −0.20 | 0.42 | −4.18# | −3.67# | −4.02# | −0.86 |
|
| |||||||||
| Cytoskeleton organization | |||||||||
| orf19.2286 | Putative deoxyhypusine hydroxylase | −2.97 | 0.36 | −1.06 | −1.51 | −3.07# | −3.08# | −3.49# | |
|
| |||||||||
| DNA replication | |||||||||
| orf19.5183* |
| Large subunit of DNA polymerase III* | −2.60 | −4.03# | 0.98 | −0.12 | −4.07# | −3.39# | −2.58 |
| orf19.6078 |
| Putative gypsy-like reverse transcriptase | −3.48# | −0.48 | −0.43 | −6.24# | −1.66 | −4.44# | 0.28 |
| orf19.2885* |
| Putative DNA primase* | 0.27 | −3.17# | −3.27# | −3.20# | 0.35 | −2.05 | 0.31 |
| orf19.3322 |
| dUTP pyrophosphatase | −3.24# | −4.14# | −0.28 | −2.23 | −3.38# | −4.36# | −0.44 |
|
| |||||||||
| Ergosterol biosynthesis | |||||||||
| orf19.1631* |
| Delta(24)-sterol C-methyltransferase* | −0.67 | 0.20 | −3.61# | −2.84 | −6.05# | −4.09# | −1.34 |
| orf19.2016* | Possible role in ergosterol biosynthesis* | −2.26 | 0.16 | 2.13 | −3.22# | −3.69# | −3.14# | 1.05 | |
| orf19.922* |
| Lanosterol 14-alpha-demethylase* | −1.29 | −0.44 | −0.73 | −5.19# | −4.14# | −5.50# | −2.26 |
|
| |||||||||
| Filamentous growth | |||||||||
| orf19.815 |
| Putative guanine nucleotide exchange factor required for embedded filamentous growth | −1.76 | −4.90# | −0.07 | 0.47 | −4.22# | −1.11 | −4.89# |
| orf19.3669 |
| Putative serine/threonine kinase | −1.04 | −2.35 | −0.77 | −3.24# | −3.27# | −1.55 | −3.89# |
| orf19.3575* |
| Putative pyruvate kinase; mutation affects filamentation* | −2.04 | −0.07 | 0.20 | −3.09# | −3.12# | −3.97# | 0.49 |
|
| |||||||||
| Gluconeogenesis | |||||||||
| orf19.7514* | PCK1* | Phosphoenolpyruvate carboxykinase* | −0.22 | −3.90# | 2.82 | 1.21 | −3.89# | −3.66# | −2.91 |
|
| |||||||||
| Glutathione biosynthetic process | |||||||||
| orf19.5059 |
| Gamma-glutamylcysteine synthetase | −2.60 | −3.06# | −3.10# | 1.00 | −2.27 | −0.52 | −3.85# |
|
| |||||||||
| Intracellular transport | |||||||||
| orf19.4805 | Putative membrane protein | −1.19 | 1.35 | −0.56 | −3.69# | −3.87# | −3.64# | −2.47 | |
|
| |||||||||
| Lipoate biosynthetic process | |||||||||
| orf19.819 | Possible role in lipoate biosynthesis | −1.06 | −3.54# | 1.91 | 0.27 | −4.15# | −3.69# | −0.94 | |
|
| |||||||||
| NAD biosynthetic process | |||||||||
| orf19.1460 | Putative glutamine-dependent NAD synthetase | −2.41 | −2.49 | 0.05 | −0.79 | −3.60# | −3.23# | −3.51# | |
|
| |||||||||
| Oxidation/Reduction | |||||||||
| orf19.5517 | Similar to alcohol dehydrogenases | −2.94 | −0.19 | −0.85 | −4.83# | −6.56# | −8.21# | −0.07 | |
| orf19.2525 |
| Mitochondrial homoisocitrate dehydrogenase | −2.17 | 1.04 | −1.19 | −5.01# | −5.72# | −7.22# | 0.65 |
|
| |||||||||
| RNA processing | |||||||||
| orf19.7215 | Ortholog(s) have snoRNA binding activity | −2.83 | −0.06 | −0.38 | −0.16 | −5.20# | −4.12# | −3.23# | |
| orf19.3159 |
| Similar to | −1.27 | −0.48 | −0.20 | −2.29 | −5.60# | −3.26# | −3.15# |
|
| |||||||||
| Signaling | |||||||||
| orf19.3453 | Possible role in signal transduction | −1.58 | −0.21 | 0.89 | −4.27# | −3.25# | −4.07# | 0.09 | |
| orf19.6906* |
| Protein described as part of 40S ribosomal subunit* | −3.30# | −2.92 | −1.91 | 0.37 | −3.74# | −4.70# | −2.62 |
|
| |||||||||
| TCA cycle | |||||||||
| orf19.6632 |
| Aconitate hydratase 2 | −1.14 | −0.25 | 0.55 | −3.34# | −6.53# | −4.39# | 0.05 |
|
| |||||||||
| Translation | |||||||||
| orf19.6253* |
| Putative ribosomal protein* | −1.19 | −3.68# | −0.63 | −3.51# | −2.82 | −2.86 | −3.17# |
| orf19.4152* |
| Translation elongation factor 3* | −2.13 | −3.35# | 0.54 | 0.12 | −3.18# | −1.03 | −3.86# |
|
| |||||||||
| Transport | |||||||||
| orf19.4599 |
| Putative phosphate permease | 0.73 | −0.06 | −2.63 | −11.05# | −6.49# | −5.80# | −6.50# |
| orf19.5170 |
| Possible sodium transporter sodium transporters | −0.77 | −2.46 | −1.35 | −3.59# | −4.30# | −5.16# | −1.38 |
| orf19.6000* |
| ABC transporter involved in multidrug resistance* | −0.09 | −0.21 | −2.97 | −1.76 | −5.00# | −5.04# | −3.82# |
|
| |||||||||
| Unknown | |||||||||
| orf19.7413 | MMS21-SMC5-SMC6 complex component | −3.01# | −3.22# | 1.62 | −3.10# | −1.53 | −1.75 | 0.55 | |
| orf19.1549 | Unknown | −0.42 | −1.89 | −3.17# | −3.96# | −3.83# | −2.95 | −1.10 | |
| orf19.4651 |
| Putative GPI-anchored protein | −0.84 | −1.33 | −1.16 | −3.73# | −3.33# | −3.75# | 0.35 |
| orf19.5799 | Unknown | 0.24 | −0.13 | −1.23 | −3.54# | −4.95# | −5.27# | −1.11 | |
| orf19.915 | Unknown | −0.56 | 1.05 | −0.59 | 0.19 | −3.60# | −3.15# | −3.21# | |
| orf19.5760 |
| Putative GPI-anchored protein | −2.64 | −5.84# | −0.54 | −5.21# | −3.27# | −5.36# | −5.36# |
| orf19.3548 | Unknown | −3.48# | −1.88 | −0.44 | 1.89 | −3.13# | −3.08# | −0.96 | |
aFor further information on the open reading frames (ORFs) see the Candida Genome Database (CGD: [20]) (http://www.candidagenome.org/).
bInformation on the molecular function is abridged. More information is available at the CGD website.
cFunctional groupings derived from Biological Process GO annotations. Due to space restrictions, the groupings are simplified. Individual genes can be involved in multiple biological processes.